Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 75rÜ 10tk; 75rÜ 1tk; 75rÜ 5tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 150rÜ 5tk; 150rÜ 1tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 150rÜ 10tk; 150rÜ 1tk; 150rÜ 5tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 75rÜ 10tk; 75rÜ 5tk; 75rÜ 1tk

Eesti - eesti - Ravimiamet

ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 900rÜ 1tk

Eesti - eesti - Ravimiamet

ferring gmbh - menopausaalne humaangonadotropiin - süstelahus pen-süstlis - 600rÜ 1tk

Eesti - eesti - Ravimiamet

ferring gmbh - menopausaalne humaangonadotropiin - süstelahus pen-süstlis - 1200rÜ 1tk

Eesti - eesti - Ravimiamet

ferring gmbh - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 75rÜ 5tk; 75rÜ 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

gedeon richter plc. - follitropiin alfa - anovulatsioon - suguhormoonid ja genitaalsüsteemi, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. kliinilistes uuringutes on nendel patsientidel olid määratletud on endogeensed seerumi lh tase < 1. 2 rÜ / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degareliks - eesnäärmevähk - endokriinset ravi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.